表紙:世界のファーマコビジランス (医薬品安全性監視) の アウトソーシング市場:タイプ別・サービスプロバイダ別・エンドユーザー別-機会分析および業界予測(2021年~2030年)
市場調査レポート
商品コード
1030176

世界のファーマコビジランス (医薬品安全性監視) の アウトソーシング市場:タイプ別・サービスプロバイダ別・エンドユーザー別-機会分析および業界予測(2021年~2030年)

Pharmacovigilance Outsourcing Market by Type, Service Provider, and End User : Global Opportunity Analysis and Industry Forecast, 2021-2030.

出版日: | 発行: Allied Market Research | ページ情報: 英文 278 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.03円
世界のファーマコビジランス (医薬品安全性監視) の アウトソーシング市場:タイプ別・サービスプロバイダ別・エンドユーザー別-機会分析および業界予測(2021年~2030年)
出版日: 2021年07月01日
発行: Allied Market Research
ページ情報: 英文 278 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のファーマコビジランスのアウトソーシング市場規模は、2020年に24億8,910万米ドルに達しました。

2030年には96億5,410万米ドルに達すると予測され、2020年から2030年の間に14.60%のCAGRで成長すると予想されています。

ファーマコビジランスのアウトソーシングサービスには、低コストで運用コストを最小限に抑えられるという利点があるため、製薬企業、病院、各種研究機関によるアウトソーシングサービスへの関心が高まっています。また、医薬品に関連した副作用や薬毒物の増加は、市場の成長を促進する主な要因の一つとなっています。

さらに、安全性への懸念から注目度の高い医薬品のリコールが発生すると、規制当局による医療情報の必要性が高まり、これが市場の成長を促進すると予想されています。しかし、サイバー脅威、サイバー攻撃、破壊的な力や許可されていないユーザーの意図しない行動によるデータ侵害など、データセキュリティに関連するリスクや、コンプライアンスを維持するための熟練した専門家の不足などが市場の成長を抑制しています。

当レポートでは、世界のファーマコビジランスのアウトソーシング市場について調査しており、市場力学、市場機会、市場分析、競合情勢、企業プロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
    • 主な成功戦略
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング(2020年)
  • 市場力学
    • 促進要因
      • アウトソーシングサービスの好みの増加
      • 副作用と薬物毒性の上昇
      • 知名度の高い薬物のリコール
    • 抑制要因
      • データセキュリティに関連するリスク
      • 熟練した専門家の不足
    • 市場機会
      • 新興市場における成長機会
    • 影響分析
  • COVID-19によるファーマコビジランスのアウトソーシング市場への影響分析

第4章 ファーマコビジランスのアウトソーシング市場:タイプ別

  • 概要
    • 市場規模と予測
  • 副作用捕捉(ADR)
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • ケース処理
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測
    • 市場分析:国別
  • 報告と提出
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • レポートの公開
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 品質検査
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 危機管理
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 知財管理
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • アーキテクチャの有効化
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別

第5章 ファーマコビジランスのアウトソーシング市場:サービスプロバイダー別

  • 概要
    • 市場規模と予測
  • 委託調査機関
    • 市場規模と予測:地域別
    • 市場分析:国別
    • 市場規模と予測:エンドユーザー別
  • ビジネスプロセスアウトソーシング
    • 市場規模と予測
    • 市場分析:国別
    • 市場規模と予測:エンドユーザー別

第6章 ファーマコビジランスのアウトソーシング市場:エンドユーザー別

  • 概要
    • 市場規模と予測
  • 製薬業界
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 研究機関
    • 市場規模と予測:地域別
    • 市場分析:国別
  • その他
    • 市場規模と予測
    • 市場分析:国別

第7章 ファーマコビジランスのアウトソーシング市場:地域別

  • 概要
    • 市場規模と予測
  • 北米
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:国別
      • 米国
      • カナダ
      • メキシコ
    • 北米の市場規模と予測:タイプ別
    • 北米の市場規模と予測:サービスプロバイダー別
    • 北米の市場規模と予測:エンドユーザー別
  • 欧州
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他
    • 欧州の市場規模と予測:タイプ別
    • 欧州の市場規模と予測:サービスプロバイダー別
    • 欧州の市場規模と予測:エンドユーザー別
  • アジア太平洋
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:国別
      • 日本
      • 中国
      • オーストラリア
      • インド
      • 韓国
      • その他
    • アジア太平洋の市場規模と予測:タイプ別
    • アジア太平洋の市場規模と予測:サービスプロバイダー別
    • アジア太平洋の市場規模と予測:エンドユーザー別
  • ラテンアメリカ・中東・アフリカ
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ
      • その他
    • ラテンアメリカ・中東・アフリカの市場規模と予測:タイプ別
    • ラテンアメリカ・中東・アフリカの市場規模と予測:サービスプロバイダー別
    • ラテンアメリカ・中東・アフリカの市場規模と予測:エンドユーザー別

第8章 企業プロファイル

  • ACCENTURE PLC.
  • BIOCLINICA INC.
  • CAPGEMINI(IGATE CORPORATION)
  • COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
  • ERGOMED PLC.
  • GENPACT LIMITED
  • INTERNATIONAL BUSINESS MACHINES CORPORATION
  • ICON PLC
  • IQVIA HOLDINGS INC.(CLINTEC)
  • LABCORP DRUG DEVELOPMENT(COVANCE)
図表

LIST OF TABLES

  • TABLE 01.PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030($MILLION)
  • TABLE 02.ADVERSE DRUG REACTION CAPTURE (ADR) PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.CASE PROCESSING PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 04.REPORTING AND SUBMISSION PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 05.REPORT PUBLISHING PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 06.QUALITY CHECK PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 07.RISK MANAGEMENT PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 08.KNOWLEDGE MANAGEMENT PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 09.ENABLING ARCHITECTURE PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 10.PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030($MILLION)
  • TABLE 11.CONTRACT RESEARCH ORGANIZATIONS PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 12.CONTRACT RESEARCH ORGANIZATION PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 13.BUSINESS PROCESSING OUTSOURCING PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 14.BUSINESS PROCESSING OUTSOURCING PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 15.PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030($MILLION)
  • TABLE 16.PHARMACEUTICAL INDUSTRY PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 17.RESEARCH ORGANIZATION PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 18.OTHERS PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 19.PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020-2030($MILLION)
  • TABLE 20.NORTH AMERICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 21.U.S. PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 22.U.S. PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 23.U.S. PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 24.CANADA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 25.CANADA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 26.CANADA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 27.MEXICO PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 28.MEXICO PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 29.MEXICO PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 30.NORTH AMERICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 31.NORTH AMERICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 32.NORTH AMERICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 33.EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 34.GERMANY PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 35.GERMANY PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030($MILLION)
  • TABLE 36.GERMANY PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 37.FRANCE PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 38.FRANCE PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 39.FRANCE PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 40.UK PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 41.UK PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 42.UK PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 43.ITALY PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 44.ITALY PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 45.ITALY PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 46.SPAIN PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 47.SPAIN PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 48.SPAIN PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 49.REST OF EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 50.REST OF EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 51.REST OF EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 52.EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 53.EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 54.EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 55.ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 56.JAPAN PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 57.JAPAN PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 58.JAPAN PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 59.CHINA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 60.CHINA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 61.CHINA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 62.AUSTRALIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 63.AUSTRALIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 64.AUSTRALIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 65.INDIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 66.INDIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 67.INDIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 68.SOUTH KOREA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 69.SOUTH KOREA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 70.SOUTH KOREA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 71.REST OF ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 72.REST OF ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 73.REST OF ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 74.ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 75.ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 76.ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 77.LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 78.BRAZIL PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 79.BRAZIL PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 80.BRAZIL PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 81.SAUDI ARABIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 82.SAUDI ARABIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 83.SAUDI ARABIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 84.SOUTH AFRICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 85.SOUTH AFRICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 86.SOUTH AFRICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER 2020-2030 ($MILLION)
  • TABLE 87.REST OF LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 88.REST OF LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 89.REST OF LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, END USER, 2020-2030 ($MILLION)
  • TABLE 90.LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 91.LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020-2030 ($MILLION)
  • TABLE 92.LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 93.ACCENTURE PLC.: COMPANY SNAPSHOT
  • TABLE 94.ACCENTURE PLC.: PRODUCT SEGMENTS
  • TABLE 95.ACCENTURE PLC.: PRODUCT PORTFOLIO
  • TABLE 96.BIOCLINICA INC. COMPANY: COMPANY SNAPSHOT
  • TABLE 97.BIOCLINICA INC.: OPERATING SEGMENTS
  • TABLE 98.BIOCLINICA INC.: PRODUCT PORTFOLIO
  • TABLE 99.CAPGEMINI: COMPANY SNAPSHOT
  • TABLE 100.CAPGEMINI: OPERATING SEGMENTS
  • TABLE 101.CAPGEMINI: PRODUCT PORTFOLIO
  • TABLE 102.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT
  • TABLE 103.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION : OPERATING SEGMENTS
  • TABLE 104.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 105.ERGOMED PLC: COMPANY SNAPSHOT
  • TABLE 106.ERGOMED PLC: OPERATING SEGMENTS
  • TABLE 107.ERGOMED PLC: PRODUCT PORTFOLIO
  • TABLE 108.GENPACT LIMITED: COMPANY SNAPSHOT
  • TABLE 109.GENPACT LIMITED: OPERATING SEGMENT
  • TABLE 110.GENPACT LIMITED: PRODUCT PORTFOLIO
  • TABLE 111.INTERNATIONAL BUSINESS MACHINES CORPORATION: COMPANY SNAPSHOT
  • TABLE 112.INTERNATIONAL BUSINESS MACHINES CORPORATION: OPERATING BUSINESS SEGMENTS
  • TABLE 113.INTERNATIONAL BUSINESS MACHINES CORPORATION: PRODUCT PORTFOLIO
  • TABLE 114.ICON PLC: COMPANY SNAPSHOT
  • TABLE 115.ICON PLC: PRODUCT PORTFOLIO
  • TABLE 116.IQVIA INC: COMPANY SNAPSHOT
  • TABLE 117.IQVIA INC: OPERATING SEGMENTS
  • TABLE 118.IQVIA INC: PRODUCT PORTFOLIO
  • TABLE 119.LABCORP DRUG DEVELOPMENT: COMPANY SNAPSHOT
  • TABLE 120.LABCORP DRUG DEVELOPMENT: OPERATING BUSINESS SEGMENTS
  • TABLE 121.LABCORP DRUG DEVELOPMENT: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.PHARMACOVIGILANCE OUTSOURCING MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 10.HIGH INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF ADVERSE DRUG REACTION CAPTURE (ADR) PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF CASE PROCESSING PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF REPORTING AND SUBMISSION PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF REPORT PUBLISHING PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF QUALITY CHECK PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF RISK MANAGEMENT PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF KNOWLEDGE MANAGEMENT PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 20.COMPARATIVE ANALYSIS OF ENABLING ARCHITECTURE PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 21.COMPARATIVE ANALYSIS OF CONTRACT RESEARCH ORGANIZATIONS PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF BUSINESS PROCESSING OUTSOURCING PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF PHARMACEUTICAL INDUSTRY PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 24.COMPARATIVE ANALYSIS OF RESEARCH ORGANIZATION PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 25.COMPARATIVE ANALYSIS OF OTHERS PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 26.ACCENTURE PLC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 27.ACCENTURE PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 28.ACCENTURE PLC: REVENUE SHARE, BY REGION, 2020(%)
  • FIGURE 29.CAPGEMINI: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 30.CAPGEMINI: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 31.CAPGEMINI: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 32.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 33.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 34.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: REVENUE SHARE, BY REGION, 2020(%)
  • FIGURE 35.ERGOMED PLC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 36.ERGOMED PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 37.ERGOMED PLC: REVENUE SHARE, BY REGION, 2020(%)
  • FIGURE 38.GENPACT LIMITED: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 39.GENPACT LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 40.GENPACT LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 41.INTERNATIONAL BUSINESS MACHINES CORPORATION: NET SALES, 2018-2020 ($MILLION
  • FIGURE 42.INTERNATIONAL BUSINESS MACHINES CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 43.INTERNATIONAL BUSINESS MACHINES CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 44.ICON PLC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 45.ICON PLC: REVENUE SHARE, BY REGION, 2020(%)
  • FIGURE 46.IQVIA HOLDINGS INC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 47.IQVIA HOLDINGS INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 48.IQVIA HOLDINGS INC: REVENUE SHARE, BY REGION, 2020(%)
  • FIGURE 49.LABCORP DRUG DEVELOPMENT: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 50.LABCORP DRUG DEVELOPMENT: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 51.LABCORP DRUG DEVELOPMENT: REVENUE SHARE, BY REGION, 2020 (%)
目次
Product Code: A10915

The global pharmacovigilance outsourcing market was valued at $2,489.10 million in 2020, and is projected to reach $9,654.10 million by 2030 registering a CAGR of 14.60% from 2021 to 2030.

Pharmacovigilance outsourcing is transfer of drug safety operations and processes to a third-party service provider by a life science firm. Primary pharmacovigilance outsourcing activities include case processing and compliance management. Apart from this, pharmacovigilance outsourcing activities also include core activities and management activities.

Core pharmacovigilance outsourcing activities encompass gathering data associated with adverse drug reaction (ADR), preparation of risk management strategies as well as risk assessment mitigation strategies, and creation submission of expedited & aggregate pharmacovigilance reports. Furthermore, management pharmacovigilance outsourcing activities comprise preparing standard operating procedures as well as other controlled quality documents. In addition, it also includes supporting internal & external compliance reporting, testing, and checking business processes & systems for compliance, carrying out trend analyses & predictive modeling for compliance functions, and formulating comprehensive descriptions of the pharmacovigilance system. Apart from this, management pharmacovigilance outsourcing activities also consist of drafting or revising safety data exchange contracts with third parties or business partners, inspecting readiness training, checking pharmacovigilance system updates, and developing & implementing corrective and preventive action (CAPA) policies.

Increase in preference for outsourcing services by the pharmaceutical industry, hospitals, and various research organizations, owing to benefits associated with pharmacovigilance outsourcing services such as low cost and minimum operational expenses. In addition, rise in adverse drug reactions and drug toxicity associated with pharmaceutical products is one of the major factors that propels the market growth. Furthermore, high profile drug recalls due to safety concerns also increases the need for medical information by regulatory authorities, which is anticipated to fuel growth of the market. However, risk associated with data security including cyber threats, cyberattacks, or data breach from destructive forces and from unwanted actions of unauthorized users as well as dearth of skilled professionals for maintaining compliance restraint growth of the market. In contrast, growth opportunities in emerging markets, owing to availability of cost-effective pharmacovigilance outsourcing services provided by leading CROs and BPOs in emerging economies create lucrative opportunities for the pharmacovigilance outsourcing market.

The global pharmacovigilance outsourcing market is segmented on the basis of type, service providers, end user, and region. By type, the market is divided into adverse drug reaction capture (ADR), case processing, reporting and submission, report publishing, quality check, risk management, knowledge management, and enabling architecture. On the basis of service provider, it is segmented into contract research organizations and business processing outsourcing. By end user, it is divided into pharmaceutical industry, research organizations, and others. The others segment is further divided into regulatory organizations and hospitals. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global pharmacovigilance outsourcing market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and services of pharmacovigilance outsourcing used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Type

  • Adverse Drug Reaction Capture (ADR)
  • Case Processing
  • Reporting and Submission
  • Report Publishing
  • Quality Check
  • Risk Management
  • Knowledge Management
  • Enabling Architecture

By Service Provider

  • Contract Research Organization
  • Business Processing Outsourcing

By End User

  • Pharmaceutical Industry
  • Research Organization
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Accenture PLC.
  • Bioclinica
  • Capgemini (IGate Corporation)
  • Cognizant Technology Solutions Corporation
  • Ergomed Plc.
  • Genpact Limited
  • International Business Machines Corporation
  • Icon Plc
  • IQVIA Holdings Inc. (Clintec)
  • Labcorp Drug Development (Covance)

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increase in preferences for outsourcing services
      • 3.5.1.2.Rise in adverse drug reactions and drug toxicity
      • 3.5.1.3.High profile drug recalls
    • 3.5.2.Restraints
      • 3.5.2.1.Risk associated with data security
      • 3.5.2.2.Dearth of skilled professionals
    • 3.5.3.Opportunities
      • 3.5.3.1.Growth opportunities in emerging markets
    • 3.5.4.Impact analysis
  • 3.6.COVID-19 Impact analysis on the pharmacovigilance outsourcing market

CHAPTER 4:PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Adverse Drug Reaction Capture (ADR)
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Case Processing
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Reporting and Submission
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Report Publishing
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
  • 4.6.Quality Check
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country
  • 4.7.Risk Management
    • 4.7.1.Key market trends, growth factors, and opportunities
    • 4.7.2.Market size and forecast, by region
    • 4.7.3.Market analysis, by country
  • 4.8.Knowledge Management
    • 4.8.1.Key market trends, growth factors, and opportunities
    • 4.8.2.Market size and forecast, by region
    • 4.8.3.Market analysis, by country
  • 4.9.Enabling Architecture
    • 4.9.1.Key market trends, growth factors, and opportunities
    • 4.9.2.Market size and forecast, by region
    • 4.9.3.Market analysis, by country

CHAPTER 5:PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Contract Research Organizations
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
    • 5.2.3.Market size and forecast, by end user
  • 5.3.Business Processing Outsourcing
    • 5.3.1.Market size and forecast
    • 5.3.2.Market analysis, by country
    • 5.3.3.Market size and forecast, by end user

CHAPTER 6:PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Pharmaceutical Industry
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Research Organization
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Others
    • 6.4.1.Market size and forecast
    • 6.4.2.Market analysis, by country

CHAPTER 7:PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
      • 7.2.2.1.U.S.
      • 7.2.2.1.1.U.S. pharmacovigilance outsourcing market, by type
      • 7.2.2.1.2.U.S. pharmacovigilance outsourcing market, by service provider
      • 7.2.2.1.3.U.S. pharmacovigilance outsourcing market, by end user
      • 7.2.2.2.Canada
      • 7.2.2.2.1.Canada pharmacovigilance outsourcing market, by type
      • 7.2.2.2.2.Canada pharmacovigilance outsourcing market, by service provider
      • 7.2.2.2.3.Canada pharmacovigilance outsourcing market, by end user
      • 7.2.2.3.Mexico
      • 7.2.2.3.1.Mexico pharmacovigilance outsourcing market, by type
      • 7.2.2.3.2.Mexico pharmacovigilance outsourcing market, by service provider
      • 7.2.2.3.3.Mexico pharmacovigilance outsourcing market, by end user
    • 7.2.3.North America market size and forecast, by type
    • 7.2.4.North America market size and forecast, by service provider
    • 7.2.5.North America market size and forecast, by end user
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Germany pharmacovigilance outsourcing market, by type
      • 7.3.2.1.2.Germany pharmacovigilance outsourcing market, by service provider
      • 7.3.2.1.3.Germany pharmacovigilance outsourcing market, by end user
      • 7.3.2.2.France
      • 7.3.2.2.1.France pharmacovigilance outsourcing market, by type
      • 7.3.2.2.2.France pharmacovigilance outsourcing market, by service provider
      • 7.3.2.2.3.France pharmacovigilance outsourcing market, by end user
      • 7.3.2.3.UK
      • 7.3.2.3.1.UK pharmacovigilance outsourcing market, by type
      • 7.3.2.3.2.UK pharmacovigilance outsourcing market, by service provider
      • 7.3.2.3.3.UK pharmacovigilance outsourcing market, by end user
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Italy pharmacovigilance outsourcing market, by type
      • 7.3.2.4.2.Italy pharmacovigilance outsourcing market, by service provider
      • 7.3.2.4.3.Italy pharmacovigilance outsourcing market, by end user
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Spain pharmacovigilance outsourcing market, by type
      • 7.3.2.5.2.Spain pharmacovigilance outsourcing market, by service provider
      • 7.3.2.5.3.Spain pharmacovigilance outsourcing market, by end user
      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Rest of Europe pharmacovigilance outsourcing market, by type
      • 7.3.2.6.2.Rest of Europe pharmacovigilance outsourcing market, by service provider
      • 7.3.2.6.3.Rest of Europe pharmacovigilance outsourcing market, by end user
    • 7.3.3.Europe market size and forecast, by type
    • 7.3.4.Europe market size and forecast, by service provider
    • 7.3.5.Europe market size and forecast, by end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
      • 7.4.2.1.Japan
      • 7.4.2.1.1.Japan pharmacovigilance outsourcing market, by type
      • 7.4.2.1.2.Japan pharmacovigilance outsourcing market, by service provider
      • 7.4.2.1.3.Japan pharmacovigilance outsourcing market, by end user
      • 7.4.2.2.China
      • 7.4.2.2.1.China pharmacovigilance outsourcing market, by type
      • 7.4.2.2.2.China pharmacovigilance outsourcing market, by service provider
      • 7.4.2.2.3.China pharmacovigilance outsourcing market, by end user
      • 7.4.2.3.Australia
      • 7.4.2.3.1.Australia pharmacovigilance outsourcing market, by type
      • 7.4.2.3.2.Australia pharmacovigilance outsourcing market, by service provider
      • 7.4.2.3.3.Australia pharmacovigilance outsourcing market, by end user
      • 7.4.2.4.India
      • 7.4.2.4.1.India pharmacovigilance outsourcing market, by type
      • 7.4.2.4.2.India pharmacovigilance outsourcing market, by service provider
      • 7.4.2.4.3.India pharmacovigilance outsourcing market, by end user
      • 7.4.2.5.South Korea
      • 7.4.2.5.1.South Korea pharmacovigilance outsourcing market, by Type
      • 7.4.2.5.2.South Korea pharmacovigilance outsourcing market, by service provider
      • 7.4.2.5.3.South Korea pharmacovigilance outsourcing market, by end user
      • 7.4.2.6.Rest of Asia-Pacific
      • 7.4.2.6.1.Rest of Asia-Pacific pharmacovigilance outsourcing market, by type
      • 7.4.2.6.2.Rest of Asia-Pacific pharmacovigilance outsourcing market, by service provider
      • 7.4.2.6.3.Rest of Asia-Pacific pharmacovigilance outsourcing market, by end user
    • 7.4.3.Asia-Pacific market size and forecast, by type
    • 7.4.4.Asia-Pacific market size and forecast, by service provider
    • 7.4.5.Asia-Pacific market size and forecast, by end user
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
      • 7.5.2.1.Brazil
      • 7.5.2.1.1.Brazil pharmacovigilance outsourcing market, by type
      • 7.5.2.1.2.Brazil pharmacovigilance outsourcing market, by service provider
      • 7.5.2.1.3.Brazil pharmacovigilance outsourcing market, by end user
      • 7.5.2.2.Saudi Arabia
      • 7.5.2.2.1.Saudi Arabia pharmacovigilance outsourcing market, by type
      • 7.5.2.2.2.Saudi Arabia pharmacovigilance outsourcing market, by service provider
      • 7.5.2.2.3.Saudi Arabia pharmacovigilance outsourcing market, by end user
      • 7.5.2.3.South Africa
      • 7.5.2.3.1.South Africa pharmacovigilance outsourcing market, by type
      • 7.5.2.3.2.South Africa pharmacovigilance outsourcing market, by service provider
      • 7.5.2.3.3.South Africa pharmacovigilance outsourcing market, by end user
      • 7.5.2.4.Rest of LAMEA
      • 7.5.2.4.1.Rest of LAMEA pharmacovigilance outsourcing market, by type
      • 7.5.2.4.2.Rest of LAMEA pharmacovigilance outsourcing market, by service provider
      • 7.5.2.4.3.Rest of LAMEA pharmacovigilance outsourcing market, by end user
    • 7.5.3.LAMEA market size and forecast, by type
    • 7.5.4.LAMEA market size and forecast, by service provider
    • 7.5.5.LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.ACCENTURE PLC.
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.BIOCLINICA INC.
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Key strategic moves and developments
  • 8.3.CAPGEMINI (IGATE CORPORATION)
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
  • 8.5.ERGOMED PLC.
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.GENPACT LIMITED
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
  • 8.7.INTERNATIONAL BUSINESS MACHINES CORPORATION
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.ICON PLC
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.IQVIA HOLDINGS INC.(CLINTEC)
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.LABCORP DRUG DEVELOPMENT (COVANCE)
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
    • 8.10.6.Key strategic moves and developments